Company news

PharmaEngine, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

XtalPi AI Drug Discovery Collaboration Reaches Milestone as PharmaEngine's Novel PRMT5 Inhibitor PEP08 Receives Clinical Trial Approvals

September 9, 2025

Phase III RESILIENT trial evaluating Onivyde in second-line monotherapy for small cell lung cancer did not meet its primary endpoint

August 3, 2022

PharmaEngine to attend 1H22 financial status investor conference hosted by Cathay Securities

July 26, 2022

PharmaEngine announces the board resolutions on approving the Second Quarter of 2022 consolidated financial report

July 26, 2022

Announcement on the record date for the capital increase of Employee Restricted Shares and related matters

July 26, 2022

Announcement of the resolution by the company’s board of directors for the ex-dividend record date of cash dividends

July 26, 2022

The Company announced the new-elected members of the Compensation Committee

May 27, 2022

The Company announced the new-elected members of the Audit Committee

May 27, 2022

PharmaEngine: Important resolutions of the Company's 2022 Annual Shareholders' Meeting

May 27, 2022

Announcement of the new chairperson of The Company

May 27, 2022

Announcement of the 2022 shareholders' meeting resolution of new-elected 9 directors (including 3 independent directors)

May 27, 2022

PharmaEngine to attend Cathay Securities Investor Conference hosted by Cathay Securities

April 28, 2022

PharmaEngine announces the board resolutions on approving the First Quarter of 2022 consolidated financial report.

April 28, 2022

PharmaEngine announced that the China NMPA has granted approval for ONIVYDE Regimen for the Treatment of Metastatic Pancreatic Cancer

April 15, 2022

PharmaEngine to attend Yuanta Securities Investor Conference hosted by Yuanta Securities

March 8, 2022

Announcement that the Company's Board of Directors resolved to issue restricted stock awards (RSA)

March 8, 2022

PharmaEngine announces the board resolutions on approving the Full Year of 2021 consolidated financial report.

March 8, 2022

Announcement of cancellation of the Company treasury shares and change of paid-in capital registration

March 1, 2022

PharmaEngine to attend QIC Healthcare Forum hosted by Quantum International CORP.

February 10, 2022

Decks

The 5 newest of 20 decks. Every deck is listed under its year.